COMPARATIVE-STUDIES ON VARIOUS ASSAYS FOR THE LABORATORY EVALUATION OF R-HIRUDIN

被引:21
作者
WALENGA, JM [1 ]
HOPPENSTEADT, D [1 ]
KOZA, M [1 ]
PIFARRE, R [1 ]
FAREED, J [1 ]
机构
[1] LOYOLA UNIV,MED CTR,DEPT THORAC CARDIOVASC SURG,MAYWOOD,IL 60153
关键词
D O I
10.1055/s-2007-1002597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several laboratory methods are available to measure r-hirudin, including clot-based, amidolytic, immunologic, and physicochemical techniques. The global tests, such as the PT, APTT, and Heptest, did not show an adequate response to r-hirudin in the range of 0.5 to 10.0 μg/ml, where full anticoagulation is achieved, as determined by animal models of thrombosis. The 10 U/ml thrombin time assay was very sensitive to r-hirudin, whereas the 10 U/ml calcium thrombin time gave a dose-dependent response from 0.15 to 10.0 μg/ml. Whole blood clotting assays (ACT, TEG) effectively measured r-hirudin levels up to 25 μg/ml. The amidolytic anti-Factor IIa assay, specific for evaluating direct thrombin inhibition, was very effective, particularly when modified to decrease the sample:thrombin ratio for higher r-hirudin concentrations. This assay may be useful in quality control, since it is biochemically defined and reagents are easily standardized. Thrombin generation assays based on synthetic substrates showed limited effect of r-hirudin; however assays based on TAT complex and prothrombin fragment F(1+2) generation showed a dose-dependent response. Immunologic methods (ELISA) are under development. Since these assays measure boht complexed and noncomplexed hirudin, and since they are only sensitive to submicogram levels, they may only be useful for the direct quantitation of absolute levels of r-hirudin but not for monitoring clinical anticoagulation. Thus, thrombin-based clotting, amidolytic, and immunologic assays can be used to evaluate and measure r-hirudin. However, optimization of each assay to respond to high and low concentrations of r-hirudin and their application to clinical monitoring, batch control, and standardization needs to be determined.
引用
收藏
页码:103 / 112
页数:10
相关论文
共 19 条
[1]  
[Anonymous], ENZYME LINKED IMMUNO, V12th
[2]  
BICHLER J, 1988, ARZNEIMITTEL-FORSCH, V38-1, P704
[3]   THE FUNCTIONAL DOMAIN OF HIRUDIN, A THROMBIN-SPECIFIC INHIBITOR [J].
CHANG, JY .
FEBS LETTERS, 1983, 164 (02) :307-313
[4]  
CHESEBRO JH, 1989, ANGIO ARCH, V18, P9
[5]   ISOLATION AND CHARACTERIZATION OF HIRUDIN ISOINHIBITORS AND SEQUENCE-ANALYSIS OF HIRUDIN-PA [J].
DODT, J ;
MACHLEIDT, W ;
SEEMULLER, U ;
MASCHLER, R ;
FRITZ, H .
BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1986, 367 (08) :803-811
[6]  
FAREED J, 1990, BLOOD S1, V76, pA420
[7]   DIE ISOLIERUNG UND CHEMISCHE CHARAKTERISIERUNG DES HIRUDINS [J].
MARKWARDT, F .
HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1957, 308 (2-4) :147-156
[8]  
MARKWARDT F, 1984, THROMB HAEMOSTASIS, V52, P160
[9]   DEVELOPMENT OF HIRUDIN AS AN ANTITHROMBOTIC AGENT [J].
MARKWARDT, F .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1989, 15 (03) :269-282
[10]  
MARKWARDT F, 1982, THROMB HAEMOSTASIS, V47, P225